PASI 90=≥90% improvement in Psoriasis Area and Severity Index; PASI 100=100% improvement in Psoriasis Area and Severity Index; sPGA 0/1=static Physician’s Global Assessment rating of clear or almost clear.
THE ONLY 4-DOSE-A-YEAR BIOLOGIC FOR PSORIASIS AND FOR PSORIATIC ARTHRITIS THAT OFFERS A SINGLE-DOSE PEN1
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
#1 PRESCRIPTION ANALYSIS CALCULATED BY COMBINED PRESCRIPTION DATA ACROSS Ps AND PsA
For patients with psoriatic disease, defined as those with plaque psoriasis or psoriatic arthritis. Source of data: Integrated Symphony Health (PatientSource) as of 3/2023.4
*SKYRIZI is on a preferred tier or otherwise has preferred status on the plan’s formulary.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
THE ONLY Ps TREATMENT WITH SUPERIORITY DATA VS 4 AGENTS, INCLUDING AN ORAL
Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See
‡Evaluated in patients with moderate plaque psoriasis eligible for systemic therapy.
§SOURCING: In this study, 46 patients outside of the US received non–US-licensed secukinumab. Data regarding comparability between US and non-US secukinumab are not publicly available.9
∥ACTIVE COMPARATOR: The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.
Products and their designs are trademarks of their respective owners.
MOA=Mechanism of action.
At week 161,2: 75% of Skyrizi patients (n=220/294) achieved pasi 90 in the UltIMMa-2 study vs 2% of placebo patients (n=2/98);
84% of SKYRIZI patients achieved sPGA 0/1 vs 5% of placebo patients
UltlMMa-1 results at Week 16
PASI 90: SKYRIZI 75% (n=304), placebo 5% (n=102)
sPGA 0/1: SKYRIZI 88% (n=304), placebo 8% (n=102)
Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.
p<0.0001 for comparisons of SKYRIZI vs placebo
STUDY DESIGN:
UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.1,2
At week 521,2: 81% of Skyrizi patients (n=237/294) achieved pasi 90 in the UltIMMa-2 study; placebo did not continue beyond Week 16
UltlMMa-1 results at Week 52
PASI 90: SKYRIZI 82% (n=249/304), placebo n/a
Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.
p<0.0001 for comparisons of SKYRIZI vs placebo
STUDY DESIGN:
UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.1,2
Explore
Long-term data
SKYRIZI has long-term efficacy data in Ps
(~5 years) and PsA (~2 years), and long-term safety data (~8 years in Ps, ~3 years in PsA)10-12
4 doses
per year1
3-month dosing after 2 initiation doses at Weeks 0 and 4 (150 mg/dose)1
PREFERRED¶ COVERAGE FOR >95% OF COMMERCIAL Ps AND PsA PATIENTS5#
National commercial formulary coverage under the pharmacy benefit as of May 2023
Eligible patients may be able to access their SKYRIZI at no charge until their insurance plan covers SKYRIZI**
¶SKYRIZI is on a preferred tier or otherwise has preferred status on the plan’s formulary.
#Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
**Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI® (risankizumab-rzaa) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.
